PDS Biotech to Announce Third Quarter Financial Results and Clinical Program Update
核心洞察
PDS Biotech will release its financial results for the quarter ending September 30, 2024, offering insights into its financial performance and strategic initiatives.
A conference call is scheduled for November 14, 2024, at 8:30 a.m. Eastern Time, where the company will discuss the financial results and provide a clinical program update.
PDS Biotech plans to initiate a pivotal clinical trial in 2024 to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers (搜索).
PDS Biotechnology Corporation (Nasdaq: PDSB), a late-stage immunotherapy company, will host a conference call on November 14, 2024, at 8:30 a.m. Eastern Time to report its financial results for the third quarter ended September 30, 2024, and provide an update on its clinical programs.
Conference Call Details
The conference call can be accessed via dial-in at 1-877-704-4453 or 1-201-389-0920. A live webcast and a "Call Me" registration option are also available on the company's website.
Focus on Immunotherapy and Clinical Advancements
PDS Biotech is focused on transforming how the immune system targets and eliminates cancers, as well as developing vaccines for infectious diseases. A key highlight is the planned initiation of a pivotal clinical trial in 2024 for its lead program, targeting advanced HPV16-positive head and neck squamous cell cancers (搜索).
The company's lead investigational targeted immunotherapy, Versamune® HPV, is being developed in combination with a standard-of-care immune checkpoint inhibitor. Additionally, a triple combination therapy is under investigation, including Versamune® HPV, PDS01ADC (搜索) (an IL-12 (搜索) fused antibody-drug conjugate), and a standard-of-care immune checkpoint inhibitor.
PDS Biotech believes that long-term data has demonstrated positive survival outcomes and tumor shrinkage with these combinations, alongside favorable tolerability profiles. The company is optimistic about the potential of Versamune® HPV and PDS01ADC (搜索) to disrupt tumor defenses and stimulate potent, targeted killer T-cells to attack tumors. Data from over 350 patients across multiple tumor types and treatment regimens have supported the potential broad utility of these platforms.